Pfizer Inc

NYSE: PFE
$25.77
-$0.40 (-1.5%)
Closing Price on November 26, 2024

PFE Articles

One of Cathie Wood's ARK Invest exchange-traded funds bought over 160,000 shares of Pfizer on August 23.
One of Cathie Wood's ARK Invest funds bought over 150,000 shares of Pfizer on August 18.
Tuesday's top analyst upgrades and downgrades included AbbVie, Alibaba, American Airlines, AT&T, Chipotle Mexican Grill, JD.com, Kimberly-Clark, Pfizer, Starbucks and Weyerhaeuser.
Two Dow Jones industrial average components report quarterly earnings before markets open Wednesday, along with a cannabis company that gets some attention as a meme stock.
Thursday's top analysts upgrades and downgrades included Apple, Darden Restaurants, Peloton, Pfizer, Pioneer Natural Resources, Tilray and Zynga.
Two alternative energy companies report March quarter earnings after the closing bell Monday, and three other noteworthy reports are due before Tuesday's opening bell.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including Abercrombie & Fitch, Pfizer and Teva Pharmaceutical.
Thursday's top analyst upgrades and downgrades included Apple, Best Buy, Electronic Arts, FireEye, Match, PayPal, Qualcomm and ViacomCBS.
These five outstanding stocks are rated Buy, have a least a 4% dividend and offer investors a degree of relative safety. They make sense for growth and income investors while the stock market is...
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Myovant shares shot up on Monday after the company announced a new collaboration with Pfizer for its tumor treatment across a couple of indications.
Wednesday's top analyst upgrades and downgrades included Chipotle Mexican Grill, Etsy, Exxon Mobil, General Electric, Jazz Pharmaceuticals, Microsoft, Nikola, Palo Alto Networks, Pfizer and Twitter.
BioNTech was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.